Corvus Pharmaceuticals (CRVS) Income towards Parent Company (2015 - 2026)

Corvus Pharmaceuticals' Income towards Parent Company history runs 12 years deep, the most recent figure standing at -$13.1 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 183.23% year-over-year to -$13.1 million in Q1 2026; TTM through Mar 2026 was -$30.5 million, a 11.09% decrease from a year earlier, with the FY2025 full-year figure at -$102.1 million, down 12.78% from the prior year.
• Income towards Parent Company eased to -$13.1 million in Q1 2026 per CRVS's latest filing, from -$9.8 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $15.7 million in Q1 2025 and bottomed at -$39.5 million in Q3 2024.
• The 5-year median for Income towards Parent Company is -$6.1 million (2023), against an average of -$8.0 million.
• Across the five-year window, Income towards Parent Company plunged 669.91% in 2024 and jumped 364.98% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$5.8 million in 2022, then advanced by 0.8% to -$5.7 million in 2023, then tumbled by 589.72% to -$39.5 million in 2024, then soared by 75.13% to -$9.8 million in 2025, then tumbled by 33.14% to -$13.1 million in 2026.
• Per Business Quant, the three latest CRVS Income towards Parent Company figures stand at -$13.1 million (Q1 2026), -$9.8 million (Q3 2025), and -$7.6 million (Q2 2025).